Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom
- 22 October 2009
- journal article
- research article
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 25 (4) , 470-478
- https://doi.org/10.1017/s0266462309990407
Abstract
Objectives: The aim of this study was to examine the availability and consistency of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer.Methods: A systematic review of UK economic evaluations of colorectal cancer interventions was undertaken. Searches were undertaken across ten electronic databases. Studies were critically appraised through reference to a conceptual model of UK colorectal cancer services.Results: Forty-seven studies met the inclusion criteria. There is a substantial economic evidence base surrounding population-level colorectal screening, surgical procedures, and cytotoxic therapies for the adjuvant and palliative treatment of colorectal cancer. There is limited evidence concerning the diagnosis of suspected colorectal cancer, curative treatments for metastatic disease and follow-up regimens for nonmetastatic disease. No studies were identified relating to the economics of radiotherapy, surveillance of increased-risk groups, end-of-life care, or the management of hereditary colorectal cancer. Where evidence is available, studies are subject to important differences concerning treatment options, decision criteria, and incongruent assumptions concerning the disease and its management.Conclusions: Across many aspects of the colorectal cancer service, current practice appears to have emerged without the consideration or support of economic evidence. There is a need to develop a common understanding how colorectal cancer models should be structured and implemented.Keywords
This publication has 44 references indexed in Scilit:
- An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK)European Journal Of Cancer, 2007
- Option appraisal of population-based colorectal cancer screening programmes in EnglandGut, 2007
- Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatmentBritish Journal of Cancer, 2007
- Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancerBritish Journal of Cancer, 2006
- The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancerBritish Journal of Cancer, 2006
- Short-term costs of conventional vs laparoscopic assisted surgery in patients with colorectal cancer (MRC CLASICC trial)British Journal of Cancer, 2006
- Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trialBritish Journal of Cancer, 2006
- Cost-effectiveness of combination chemotherapy (oxaliplatin or irinotecan in combination with 5-FU/FA) compared with 5-FU/FA aloneJournal of Medical Economics, 2001
- An economic comparison of the net clinical benefit and treatment costs of raltitrexed and 5-fluorouracil + leucovorin (Mayo regimen) in advanced colorectal cancerJournal of Medical Economics, 1999
- Is an immunological faecal occult blood test better than Haemoccult? A cost-benefit studyEuropean Journal of Surgical Oncology, 1995